However, more studies using clinical fibrosarcoma patient samples and in vivo animal models are needed to uphold the association of piR-39980 and its two targets, RRM2 and CYP1A2, with positive responses of fibrosarcoma patients to DOX. This evidence concerns the gene RRM2 and fibrosarcoma.